Lilly's Retatrutide Hits Phase 3 Primary Endpoint in T2D — The Drug That Could Outperform Mounjaro Is Taking Shape
By FieldPulse Staff · March 22, 2026
Tags: eli-lilly, glp-1, diabetes, obesity, phase-3
Retatrutide, Lilly's triple GIP/GLP-1/glucagon receptor agonist, met its primary endpoint in the TRANSCEND-T2D-1 trial with A1C reductions of up to 2.0% and 16.8% body weight loss at 40 weeks — even as a new safety signal emerged that is still being characterized.
Eli Lilly announced positive Phase 3 results on March 19, 2026 for retatrutide in type 2 diabetes, the first of several pivotal readouts from its TRANSCEND clinical program.
The data position retatrutide — a triple agonist hitting GIP, GLP-1, and glucagon receptors simultaneously — as a potential successor to tirzepatide (Mounjaro, Zepbound) with even greater metabolic impact.
In the TRANSCEND-T2D-1 trial of more than 2,050 enrolled patients, retatrutide met its primary endpoint: A1C reductions of up to 2.0 percentage points at 40 weeks versus placebo in adults with T2D who had inadequate glycemic control on diet and exercise alone.
Secondary endpoints were also met, including body weight reduction of up to 16.8% (approximately 36.6 lbs) and improvements in non-HDL cholesterol, triglycerides, and systolic blood pressure.
For context: tirzepatide in Phase 3 obesity trials showed mean weight loss of approximately 20-22%.
Retatrutide in earlier obesity-only Phase 3 data showed up to 26-29% body weight reduction — potentially exceeding anything currently on the market.
One note of caution: BioSpace reported that "a new safety signal emerged" in the TRANSCEND-T2D-1 data.
Lilly has not yet fully characterized the signal publicly.
Full data will be submitted for peer-reviewed publication and presented at an upcoming major medical conference.
What it means for reps: Retatrutide is Lilly's next move in the metabolic disease category, and the data suggest it will be more potent than tirzepatide.
This has two implications: Lilly reps can expect a new product in the 2027-2028 range that extends the franchise; and reps at Novo Nordisk, AstraZeneca (dapagliflozin/SGLT2), and Boehringer Ingelheim face a competitor that is likely to set a new efficacy benchmark.
Monitor the emerging safety signal carefully — it could be the defining issue at FDA review.